1. Market Research
  2. > Manufacturing
  3. > Packaging Market Trends
  4. > Prefilled Syringes Market (4th Edition), 2016 - 2026

Prefilled Syringes Market (4th Edition), 2016 - 2026

  • December 2016
  • -
  • Roots Analysis Private Ltd.
  • -
  • 533 pages

INTRODUCTION
Injectable drug delivery systems have traversed a long way from conventional syringes with vials to prefilled syringes, auto-injectors, pen injectors and needle free systems. These modern devices have become preferred devices for parenteral administration of drugs. Specifically, the demand for prefilled syringes has been rising strongly over the past several years. A growing number of healthcare facilities are now adopting this format for delivering drugs. The popularity of prefilled syringes is not limited to healthcare settings; self-injecting patients looking for easier and safer methods also prefer using prefilled syringes for drug administration in home settings. The rise in parenteral drugs, especially biologics for the treatment of diseases and chronic conditions, such as multiple sclerosis and rheumatoid arthritis, has forced drug and packaging manufacturers to seek more sophisticated container closure and drug delivery systems. Responding to this increasing preference, pharmaceutical companies are now packaging a number of their injectable drugs and vaccines in prefilled syringe format. Over 100 injectable drug products are available in prefilled syringes and a rising number of pipeline drugs are targeted to be delivered by this method.

The origins of prefilled syringes can be traced back to the early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced them as drug delivery devices for heparins in Europe. They have been around for more than three decades now and are used for administration of all major classes of therapeutics, including vaccines, anticoagulants, anti-arthritic drugs and anti-anemic drugs. Prefilled syringes have improved significantly over the years. Manufacturers have recently developed multi-chamber syringes for use with lyophilized drugs. Such syringes are also being integrated with advanced injection devices, such as autoinjectors and pen injectors. In addition, prefilled diluent syringes and flush syringes are already quite popular. With more than 60% of candidate drugs / therapies in the clinical pipeline being biologics that usually require parenteral administration, the adoption of prefilled syringes is anticipated to further increase in the mid-long term.

SCOPE OF THE REPORT
The ‘Prefilled Syringes Market (4th edition), 2016-2026’ report provides a comprehensive analysis of the current state of prefilled syringes market and the likely future evolution of these devices over the next decade. Starting with an overview on prefilled syringes, the report elaborates on the development and manufacturing of prefilled syringes. It also includes information on needlestick injuries and provides an overview of the safety laws and legislations related to prefilled syringes across the major markets in the world.

Some of the key objectives of the report were to enumerate the various prefilled syringe systems that are available in the market, identify the drugs that are available in such dosage forms and estimate their corresponding market potential across different geographical regions. Specifically, the report includes insights on:

- The current state of the market with respect to key players, targeted disease indications and the therapeutic classes of drugs that are available in the form of prefilled syringes, including a brief overview of biologics and biosimilars that are considered to be one of the primary growth drivers of this market.
- The key drugs that are available in prefilled syringes; this has been presented in the form of detailed case studies.
- The regulatory landscape in different countries, including the guidelines related to the grant of a marketing authorization for drugs in prefilled syringes.
- The candidates that are likely to be tried for delivery via prefilled syringes in the future. It is worth highlighting that the candidates were chosen based on various parameters, such as their current route of administration, targeted indication and dosage frequency.
- The key prefilled syringe and component manufacturers based in different geographies.
- Product competitiveness and supplier power (in the form of 2 X 2 matrices) across the growing landscape of glass and plastic prefilled syringes.
- Specialty syringes, which include prefilled flush syringes, prefilled diluent systems and contrast agents in prefilled syringes.
- The contract manufacturing organizations providing fill / finish services related to prefilled syringes.
- Future growth opportunities that are likely to drive the market in the short and long terms.

The study also features a detailed analysis of the existing market size and the potential future growth opportunities of these drug delivery devices across different classes of therapeutics. The analysis includes volumetric (number of units of prefilled syringes) and financial (future market size) projections of the market’s evolution over the next ten years (2016-2026). We have provided insights on the regional evolution of the prefilled syringes market covering North America, Europe (UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East). In addition, we have provided the likely evolution distributed by the type of material (glass and plastic), and nature of molecules (vaccines, biosynthetic insulins, synthetic pentasaccharides, monoclonal antibodies, small molecules). The forecast takes into account the impending price variations that are likely to emerge in the mid-long term as a result of growing adoption and increased competition. In order to account for the uncertainties associated with drug development and production, we have forecasted three different market scenarios, depicting conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with experts in this field. These included contributions from Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical Services), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), and Rondald Wheet (Chief Executive Officer, Revolutions Medical). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

1.1. RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

1.2. CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research and offers a high level view on where the market for prefilled syringes is headed in the mid-long term.

Chapter 3 provides a general overview of prefilled syringes, including details on their origin, required components (barrel, lock adapter, lubricant, needle, needle shield, plunger rod / piston, plunger stopper and tip cap) and manufacturing material (glass and plastic) . The chapter outlines the various types of prefilled syringe systems that are available in the market and provides details on the companies that manufacture such products. It also includes a discussion on the technological advances that have taken place in the recent past.

Chapter 4 highlights the growing concerns associated with needlestick injuries and the various legislative steps that have been taken to prevent them. These include installing various safety features in modern versions of prefilled syringes. In addition, the chapter provides information on some of the safety systems, including both add-on devices and device integrated features, and the companies involved in developing and manufacturing such solutions.

Chapter 5 presents information on the regulatory environment related to the grant of marketing authorizations for combination products across different countries. It highlights the role of regulatory bodies in the approval of prefilled syringes in North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 6 features a detailed discussion on the key growth drivers of the prefilled syringes market. It also describes the rise in the number of chronic diseases, the growing trend of self-injection, changing patient demographics, and the emergence of biologics / biosimilars.

Chapter 7 provides details of the various products available in the form of prefilled syringes, primarily focusing on injectable drugs and vaccines. The chapter includes case studies of some of the marketed drugs available as prefilled syringes, such as Humira®, Enbrel®, Copaxone®, Lovenox® and Abilify Maintena®. We have also captured details on the molecules that are under clinical development as prefilled syringes. The chapter features a grid analysis, representing the distribution of pipeline drugs across different therapeutic areas and different stages of clinical development. Additionally, the chapter outlines major therapeutic drug classes that are available as prefilled syringes. For each therapeutic class, we have identified the drugs that are already available in prefilled syringes, their estimated patent expiry dates and corresponding generics / biosimilars that are under development.

Chapter 8 presents a list of drug candidates (marketed / pipeline) that are likely to be tried for delivery via prefilled syringes in the future. This list is based on insights gathered on the respective routes of administration of these candidates, the nature of the indication they are prescribed for, dosage frequency and annual sales (in case of marketed drugs).

Chapter 9 provides detailed profiles of some of the key manufacturers of prefilled syringes based in different geographies. Each profile includes a brief overview of the company, its financial information, product portfolio, technology platforms, recent facility expansions and / or acquisitions, and a comprehensive future outlook. The companies that have been included in this section include Aguettant, Becton Dickinson, Gerresheimer, Nipro Corporation, Nuova Ompi, SCHOTT, Terumo Corporation, Unilife, Vetter Pharma, Weigao Group Pharmaceutical Packaging Products Company and West Pharmaceutical Services. In addition, we have included brief profiles of some of the key prefilled syringe manufacturers that are based in emerging markets. The chapter also presents 2 X 2 matrix representations, comparing product competitiveness and supplier power of both glass and plastic prefilled syringes.

Chapter 10 provides insights on the various prefilled syringe component manufacturers along with details of their respective product portfolios. The key players covered in this section include Aptar Stelmi, Datwyler and West Pharmaceutical Services.

Chapter 11 provides information on fill and finish activities and the processes and technologies associated with them. The chapter highlights the importance of aseptic fill and finish operations, and features a discussion on future trends in this segment. It also includes detailed profiles of the global players that are engaged in this segment of the industry.

Chapter 12 features information on specialty syringes, namely prefilled flush syringes, prefilled diluent systems and contrast agents that are supplied in prefilled syringes. For each type of specialty syringe, we have provided a brief overview and presented details such as the different products that are available in the market and their advantages.

Chapter 13 offers a comprehensive perspective on how the prefilled syringe market is likely to evolve over the next ten years. Based on data collected through secondary research and insights from primary research, we adopted a top-down approach in order to estimate the future size of the market, both in terms of volume (number of units) and value (in USD billion). We have projected the market’s evolution North America, Europe (UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East). In addition, we have looked at the market’s evolution by the type of material (glass and plastic) used and the nature of the product contained within the syringe (vaccines, biosynthetic insulins, synthetic pentasaccharides, monoclonal antibodies, small molecules and others). The analysis presents insightful 2 X 2 matrices based on Market Share and Market Attractiveness derived from the current and likely future state of the market.

Chapter 14 presents a list of autoinjectors that utilize prefilled syringes as their primary containers. In this chapter, we have included profiles of manufacturers of such autoinjectors, featuring an overview of the company and respective product portfolios. The key players that have been covered in this section include Bespak, DALI Medical Devices, Elcam Medical, Nuance Owen Mumford, SHL Group, Union Medico and Ypsomed Delivery Systems.

Chapter 15 discusses the recent technological developments in this domain and their applications. The chapter provides details on the advances in design technology and manufacturing of prefilled syringes that have enabled pharmaceutical companies to market lyophilized drugs in dual / multi chambered systems. The chapter highlights the advances related to novel lubrication and sterilization technologies as well.

Chapter 16 provides a comprehensive SWOT analysis of the prefilled syringes market. The chapter presents strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.

Chapter 17 summarizes the overall report. In this chapter, we have provided a recap of the key takeaways and expressed our independent opinion, based on the research and analysis described in previous chapters, on how the market is likely to fare in the shot and long terms.

Chapter 18 is a collection of interview transcripts of our discussions with some of the key players in this industry. In this chapter, we have presented the details of our conversations with Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical Services), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), and Rondald Wheet (Chief Executive Officer, Revolutions Medical).

Chapters 19 and 20 are appendices, which provide tabulated data of all the charts and the list of companies that are mentioned in the report.

EXAMPLE HIGHLIGHTS
1. Currently, more than 100 drugs and vaccines are available in prefilled syringes across different therapeutic classes. Humira®, Enbrel®, Copaxone®, Lovenox®, Rebif® and Pegasys® are examples of blockbuster drugs that are being extensively administered via prefilled syringes. In addition, over 65 drugs in prefilled syringe format are in clinical development for the treatment of number of indications such as rheumatoid arthritis and multiple sclerosis.
2. The rise of biologics has emerged as a major growth driver. Additionally, a number of biologics are getting off patent in the coming few years. Biosimilar developers will be competing for the same drug and, in such situations, use of prefilled syringes as a mode of administration can act as a key differentiator. The market’s evolution in the long-term will be fueled by pipeline drugs, technological advances and the rising adoption in developing markets. Moreover, integration of prefilled syringes with advanced delivery systems such as pen and autoinjectors will aid in gaining wider adoption.
3. The development and launch of dual / multi-chambered syringes and prefilled diluent syringes has enabled easier and faster delivery of lyophilized drugs. Novel lubrication technologies such as TriboFilm Research’s TriboGlide® and Becton Dickinson’s XSi™ coating technologies have been introduced to overcome the problems associated with the use of silicone oil. Additionally, the design and availability of silicone-free and tungsten-free syringes is making them more suitable for use with sensitive drugs such as biologics.
4. The current market is highly consolidated and is dominated by a handful of key manufacturers such as Becton Dickinson, Gerresheimer, SCHOTT, and Nuova Ompi. Other key players include West Pharmaceutical Services and Vetter Pharma; these players have already driven some novel devices and technologies in the market and are likely to foster more innovation.
5. Many regional players have recently surfaced. Specifically in China, which has a large home consumer market, domestic players have an installed annual production capacity of as high as 150 million units; Shandong Weigao Group Medical Polymer Company, Shandong Zibo Minkang Pharmaceutical Packing, and Shandong Pharmaceutical Glass are well-known players. In Japan, Arte Corporation, Nipro Corporation, Taisei Kako and Terumo Corporation are known manufacturers of prefilled syringes; similarly, Roselabs Group, an India based manufacturer has invested heavily in this area.
6. Aseptic filling of sterile drugs into prefilled syringes is one of the most crucial steps in pharmaceutical production. During the course of our study, we identified more than 45 contract manufacturing organizations, which provide fill and finish services for prefilled syringes. Majority (~70%) of the fill and finish service providers are based in North America and Europe. Prominent players in these regions include Biopharma Solutions, Catalent, Pfizer CentreOne, Rovi CM and Boehringer Ingelheim BioXcellence. Some well-known fill and finish service providers based in emerging markets include Cipla BioTec, DM Bio, Genovior Biotech and The Birgi Mefar Group.
7. We anticipate the global prefilled syringe market to grow at an annualized rate of 3.9% between 2016 and 2026. The majority share of the prefilled syringes market is currently divided between North America (35%) and the EU (45%). We believe that the prefilled syringes markets in Asia, Latin America, the Middle East and Africa are likely to grow at faster rate than those of the more developed regions.

Table Of Contents

Prefilled Syringes Market (4th Edition), 2016 - 2026
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction to Prefilled Syringes
3.1. Chapter Overview
3.2. History of Prefilled Syringes
3.3. Benefits of Prefilled Syringes over Traditional Injectable Devices
3.3.1. Benefits for Healthcare Professionals and End Users
3.3.2. Benefits for Manufacturers
3.3.3. Shift of Existing Formulations to Prefilled Syringes
3.4. Prefilled Syringes Components
3.5. Classification of Prefilled Syringes
3.5.1. Classification by Manufacturing Material of the Barrel
3.5.1.1. Glass: Historical Material of Choice
3.5.1.2. Limitations of Glass Prefilled Syringes
3.5.1.3. Addressing the Limitations of Glass Prefilled Syringes
3.5.1.4. Advantages of Plastic Prefilled Syringes
3.5.1.5. Slow Adoption of Plastic Prefilled Syringes
3.5.1.6. Factors Likely to Drive the Use of Plastic Prefilled Syringes
3.5.2. Classification by Number of Chambers in the Barrel
3.5.3. Classification by Type of Needle
3.5.4. Classification by Type of Processing
3.6. Critical Attributes of a Prefilled Syringe Design
3.7. Prefilled Syringe Systems Available in the Market
3.7.1. Glass Prefilled Syringes
3.7.2. Plastic Prefilled Syringes
3.8. Technological Developments in Prefilled Syringes
4. Needlestick Injuries
4.1. Chapter Overview
4.2. Incidence and Cost Burden
4.3. Government Legislations for Needlestick Injury Prevention
4.4. Safety Mechanisms used by Prefilled Syringe Manufacturers
4.4.1. Safety Systems: Add-On Devices
4.4.1.1. Becton Dickinson
4.4.1.2. Gerresheimer
4.4.1.3. West Pharmaceutical Services
4.4.1.4. Vetter Pharma
4.4.1.5. Tip-Top
4.4.1.6. Credence MedSystems
4.4.1.7. Schreiner MediPharm
4.4.2. Safety Systems: Integrated Devices
4.4.2.1. Unilife Corporation: Unifill Safety Syringes
4.4.2.2. MedPro Safety Products: Prefilled Safety Syringes
4.4.2.3. Taisei Kako: Fuljectâ„¢ Safety Syringes
4.4.2.4. Globe Medical Tech: Vacuum Retract Safety Syringes
4.4.2.5. US Medical Instruments: SafeSnap®
4.4.2.6. Revolutions Medical: RevVacâ„¢ Safety Syringes
4.4.2.7. MedicalChain International: MySafill® iPPFSS
4.4.2.8. Owen Mumford: Unisafeâ„¢
5. Regulatory Landscape for Prefilled Syringes
5.1. Chapter Overview
5.2. Regulatory Approval of Combination Products in the US
5.2.1. Overview
5.2.2. Historical Background
5.2.3. Regulatory Bodies and their Role in Product Approval
5.2.4. Regulatory Approval Pathway for Prefilled Syringes
5.3. Regulatory Approval of Combination Products in Europe
5.3.1. Overview
5.3.2. Regulatory Bodies and their Role in Product Approval
5.3.3. Regulatory Approval for Prefilled Syringes
5.4. Regulatory Approval of Combination Products in Canada
5.4.1. Overview
5.4.2. Regulatory Bodies and their Role in Product Approval
5.4.3. Regulatory Approval of Prefilled Syringes
5.5. Regulatory Approval of Combination Products in Brazil
5.5.1. Overview
5.5.2. Regulatory Bodies and their Role in Product Approval
5.5.3. Regulatory Approval of Prefilled Syringes
5.6. Regulatory Approval of Combination Products in Mexico
5.6.1. Overview
5.6.2. Regulatory Bodies and their Role in Product Approval
5.6.3. Regulatory Approval of Prefilled Syringes
5.7. Regulatory Approval of Combination Products in Argentina
5.7.1. Overview
5.7.2. Regulatory Bodies and their Role in Product Approval
5.7.3. Regulatory Approval of Prefilled Syringes
5.8. Regulatory Approval of Combination Products in Australia
5.8.1. Overview
5.8.2. Regulatory Bodies and their Role in Product Approval
5.8.3. Regulatory Approval of Prefilled Syringes
5.9. Regulatory Approval of Combination Products in Japan
5.9.1. Overview
5.9.2. Regulatory Bodies and their Role in Product Approval
5.9.3. Regulatory Approval of Prefilled syringes
5.10. Regulatory Approval of Combination Products in China
5.10.1. Overview
5.10.2. Regulatory Bodies and their Role in Product Approval
5.10.3. Regulatory Approval of Prefilled syringes
5.11. Regulatory Approval of Combination Products in India
5.11.1. Overview
5.11.2. Regulatory Bodies and their Role in Product Approval
5.11.3. Regulatory Approval of Prefilled Syringes
5.12. Regulatory Approval of Combination Products in South Korea
5.12.1. Overview
5.12.2. Regulatory Bodies and their Role in Product Approval
5.12.3. Regulatory Approval of Prefilled Syringes
5.13. Regulatory Approval of Combination Products in Saudi Arabia
5.13.1. Overview
5.13.2. Regulatory Bodies and their Role in Product Approval
5.14. Regulatory Approval of Prefilled Syringes
5.15. Regulatory Approval of Combination Products in United Arab Emirates
5.15.1. Overview
5.15.2. Regulatory Bodies and their Role in Product Approval
5.15.3. Regulatory Approval of Prefilled Syringes
6. Growth Drivers
6.1. Chapter Overview
6.2. Increase in the Number of Self-Injecting Patients
6.3. Increase in Incidences of Chronic Diseases
6.4. Changing Patient Demographics
6.5. Growth of Biologics and Biosimilars
6.6. Changing Pharmaceutical Strategies
6.7. Increasing Focus on the Prevention of Needlestick Injuries
6.8. Convergence of Prefilled Syringes with Autoinjectors/Pen-Injectors
7. Products Available in Prefilled Syringes
7.1. Chapter Overview
7.2. Drugs Approved in Prefilled Syringes, 2013-2016
7.3. Drugs Approved in Prefilled Syringes: Therapeutic Area Analysis
7.4. Leading Drugs in Prefilled Syringes, 2016
7.5. Other Drugs Available in Prefilled Syringes, 2016
7.6. Case Studies
7.6.1. HUMIRA® (Adalimumab), AbbVie / Eisai
7.6.1.1. Indications and Dosage Forms
7.6.1.2. Shift from Vials to Syringes
7.6.2. Enbrel® (Etanercept), Amgen / Pfizer / Takeda
7.6.2.1. Indications and Dosage Forms
7.6.2.2. Shift from Vials to Syringes
7.6.3. Copaxone® (Glatiramer Acetate), Teva Pharmaceuticals
7.6.3.1. Indications and Dosage Forms
7.6.3.2. Shift from Vials to Syringes
7.6.4. Lovenox® / Clexane® (Enoxaparin sodium), Sanofi / GL Pharma / Italfarmaco
7.6.4.1. Indications and Dosage Forms
7.6.4.2. Shift from Vials to Prefilled Syringes
7.6.5. Abilify Maintena® (Aripiprazole Controlled Release), Otsuka Pharmaceutical / Lundbeck
7.6.5.1. Indications and Dosage Forms
7.6.5.2. Shift from Vials to Syringes
7.7. Pipeline Drugs in Prefilled Syringes
7.8. Pipeline Drugs: Therapeutic Area Analysis
7.9. Drugs Available by Therapeutic Classes
7.9.1. Anti-Rheumatics
7.9.1.1. Approved Injectables
7.9.1.2. Biosimilars
7.9.2. Multiple Sclerosis Drugs
7.9.2.1. Approved Injectables
7.9.2.2. Biosimilars
7.9.3. Antivirals
7.9.3.1. Approved Injectables
7.9.3.2. Biosimilars
7.9.4. Anticoagulants
7.9.4.1. Approved Injectables
7.9.4.2. Biosimilars / Generics
7.9.5. Vaccines
7.9.6. Diabetes Drugs
7.9.6.1. Insulin Market
7.9.6.2. Approved Injectables
7.9.6.3. Biosimilars
8. Likely Candidates for Prefilled Syringes
8.1. Chapter Overview
8.2. Marketed Molecules
8.2.1. Marketed Molecules: Likely Candidates for Prefilled Syringes
8.3. Pipeline Molecules
8.3.1. Pipeline Molecules: Most Likely Candidates for Prefilled Syringes
8.3.2. Pipeline Molecules: Likely Candidates for Prefilled Syringes
8.3.3. Pipeline Molecules: Less Likely Candidates for Prefilled Syringes
8.4. Vaccines: Likely Candidates for Prefilled Syringes
9. Manufacturers of Prefilled Syringes
9.1. Chapter Overview
9.2. Key Prefilled Syringe Manufacturers Based in North America
9.2.1. Becton Dickinson
9.2.1.1. Company Overview
9.2.1.2. Financial Performance
9.2.1.3. Glass Prefilled Systems
9.2.1.3.1. BD Hypakâ„¢ Prefilled Syringe
9.2.1.3.2. Luer Products
9.2.1.3.3. Staked Needle Products
9.2.1.3.4. BD Neopakâ„¢ Prefilled Syringe
9.2.1.4. Plastic Prefilled Systems
9.2.1.4.1. BD Sterifillâ„¢ Syringe Systems
9.2.1.5. Other Prefilled Delivery Systems
9.2.1.5.1. BD Unijectâ„¢
9.2.1.5.2. BD Soluviaâ„¢
9.2.1.6. BD Prefilled Technology Solutions
9.2.1.7. Recent Developments
9.2.1.7.1. Deals and Agreements
9.2.1.7.2. Expansions
9.2.1.8. Future Outlook
9.2.2. Unilife Corporation
9.2.2.1. Company Overview
9.2.2.2. Financial Performance
9.2.2.3. Glass Prefilled Syringe
9.2.2.3.1. Unifill® Syringes
9.2.2.3.2. EZMixâ„¢ Syringes
9.2.2.4. Wearable Injector Platform
9.2.2.5. Ocular Delivery Systems
9.2.2.6. Novel Delivery Systems
9.2.2.8. Recent Developments
9.2.2.8.1. Deals and Agreements
9.2.2.8.1.1. Partnership with Amgen
9.2.2.8.1.2. Partnership with MedImmune
9.2.2.8.1.3. Partnership with AbbVie
9.2.2.8.1.4. Partnership with Global Pharma Company
9.2.2.8.1.5. Partnership with Novartis
9.2.2.8.1.6. Partnership with Hikma
9.2.2.8.1.7. Partnership with Sanofi
9.2.2.8.1.8. Partnership with Biodel
9.2.2.8.2. Expansion
9.2.2.8.3. Fundings
9.2.2.9. Future Outlook
9.2.3. West Pharmaceutical Services
9.2.3.1. Company Overview
9.2.3.2. Financial Performance
9.2.3.3. Plastic Prefilled Systems
9.2.3.3.1. Daikyo Crystal Zenith® RU Prefilled Syringe
9.2.3.4. Drug Reconstitution Systems
9.2.3.5. Prefilled Technology Solutions
9.2.3.6. Recent Developments
9.2.3.6.1. Growth of CZ Syringes
9.2.3.6.2. Launch of NovaPure Plunger for Higher Volume Injections
9.2.3.6.3. Growth in Pharma Emerging Markets (Brazil, China and India)
9.2.3.6.4. Manufacturing Expansion
9.2.3.6.5. Development Pipeline
9.2.3.7. Future Outlook
9.3. Key Prefilled Syringe Manufacturers Based in Europe
9.3.1. Aguettant
9.3.1.1. Company Overview
9.3.1.2. Aguettant Prefilled Syringes
9.3.1.3. Aguettant Self-Injector Pen
9.3.1.4. Recent Developments
9.3.1.5. Future Outlook
9.3.2. Gerresheimer
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Glass Prefilled Systems
9.3.2.3.1. Gx® Glass Syringes
9.3.2.4. Plastic Prefilled Systems
9.3.2.4.1. ClearJect® Prefilled Syringes
9.3.2.4.2. Gx RTF® Clearject® Needle Syringe
9.3.2.5. Self-Injection Devices
9.3.2.6. Prefilled Technology Solutions
9.3.2.7. Recent Developments
9.3.2.7.1. Expansion of Product Portfolio
9.3.2.7.2. Expansion of Manufacturing Capacity for RTF syringes
9.3.2.7.3. Expansion of Capacity of Medical Plastic Systems
9.3.2.7.4. Growth in Emerging Economies
9.3.2.8. Future Outlook
9.3.3. Nuova Ompi
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Glass Prefilled Systems
9.3.3.3.1. EZ-Fill® Syringes
9.3.3.4. Recent Developments
9.3.3.4.1. New Corporate Branding
9.3.3.4.2. Capacity Expansion across the Glass Divisions
9.3.3.4.3. Twist-Off Closure System for Prefilled Syringes
9.3.4. SCHOTT
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Glass Prefilled Syringes
9.3.4.3.1. syriQ® (Previously Forma 3s) Glass Syringes
9.3.4.3.2. syriQâ„¢ InJentle Syringes
9.3.4.4. Plastic Prefilled Syringes
9.3.4.4.1. TopPac® Polymer Syringes
9.3.4.5. Recent Developments
9.3.4.5.1. TopPac® Syringe System for Sensitive Drugs
9.3.4.5.2. TopPac® Syringe System for Highly Viscous Drugs
9.3.4.5.3. TopPac® 20 ml Syringe System for Infusion Therapy
9.3.4.5.4. Rebranding the Glass Prefilled Syringes
9.3.4.5.5. New Closure Systems for Plastic / Glass Prefilled System
9.3.4.5.6. Growth in the Pharma Emerging Markets (Brazil, China, India, Indonesia and Russia)
9.3.4.5.7. Expansion of Production Facilities in the US and EU
9.3.4.6. Future Outlook
9.3.5. Vetter Pharma
9.3.5.1. Company Overview
9.3.5.2. Lyo-Ject® Glass Prefilled Syringe
9.3.5.3. Vetter-Ject®
9.3.5.4. Recent Developments
9.3.5.4.1. Capacity Expansion
9.3.5.4.2. Collaboration with West Pharmaceutical Services
9.3.5.5. Future Outlook
9.4. Key Prefilled Syringes Manufacturers Based in Asia Pacific
9.4.1. Nipro Corporation (Acquired MGlas)
9.4.1.1. Company Overview
9.4.1.2. Financial Performance
9.4.1.3. Glass Prefilled Systems
9.4.1.4. Plastic Prefilled Systems
9.4.1.5. Recent Developments
9.4.1.6. Future Outlook
9.4.2. Weigao Group Pharmaceutical Packaging Products Company
9.4.2.1. Company Overview
9.4.2.2. Financial Performance
9.4.2.3. WeGo Glass Prefilled Syringe
9.4.2.4. Future Outlook
9.4.3. Terumo Corporation
9.4.3.1. Company Overview
9.4.3.2. Financial Performance
9.4.3.3. PLAJEXâ„¢: Plastic Prefilled Syringe
9.4.3.4. Safety Devices: Add-On Devices
9.4.3.5. Future Outlook
9.5. Other Manufacturers
9.5.1. Arte Corporation
9.5.2. J.O. Pharma (Subsidiary of Otsuka Holdings)
9.5.3. Roselabs Group
9.5.4. Shandong Zibo Minkang Pharmaceutical packing
9.5.5. Shandong Pharmaceutical Glass
9.5.6. Taisei Kako
9.5.7. Yangzhong Wealth Metal
9.5.8. Youlyy Industrial
9.6. Mapping the Competitive Landscape
10. Prefilled Syringe Component Manufacturers
10.1. Chapter Overview
10.2. West Pharmaceutical Services
10.2.1. Overview
10.2.2. Financial Performance
10.2.3. Prefilled Syringe Components
10.2.3.1. Plungers
10.2.3.2. Needle Shields and Tip Caps
10.2.3.3. Backstops
10.2.4. Manufacturing Facilities
10.3. Datwyler
10.3.1. Overview
10.3.2. Financial Performance
10.3.3. Prefilled Syringe Components
10.3.3.1. Plungers
10.3.3.2. Needle Shields and Tip Caps
10.3.4. Manufacturing of Prefilled Syringe Components
10.4. Aptar Stelmi
10.4.1. Overview
10.4.2. Financial Performance
10.4.3. Prefilled Syringe Components
10.4.3.1. Plungers
10.4.3.2. Needle Shields
10.4.3.3. Tip Caps
10.4.3.4. Stoppers
11. Fill-Finish Service Providers for Prefilled Syringes
11.1. Chapter Overview
11.2. Fill-Finish Processing of Prefilled Syringes
11.2.1. Steps Involved in Fill-Finish Process
11.2.2. Methods of Filling and Stoppering of Prefilled Syringes
11.2.3. Prefilled Syringe Filling Technologies
11.3. Outsourcing of Fill-Finish Operations
11.4. Growth Considerations
11.5. Fill-Finish Service Providers
11.5.1. Key Fill-Finish Service Provider(s): North America
11.5.1.1. BioPharma Solutions
11.5.1.2. Catalent
11.5.1.3. Pfizer CentreOne
11.5.2. Key Fill-Finish Service Provider(s): Latin America
11.5.2.1. PiSA Farmaceutica
11.5.3. Key Fill-Finish Service Provider(s): Europe
11.5.3.1. Boehringer Ingelheim BioXcellence
11.5.3.2. ROVI CM
11.5.4. Key Fill-Finish Service Provider(s): Asia Pacific
11.5.4.1. Cipla BioTec
11.5.4.2. DM Bio
11.5.4.3. Genovior Biotech
11.5.5. Key Fill-Finish Service Provider(s): Middle East
11.5.5.1. The Birgi Mefar Group
12. Specialty Prefilled Syringes
12.1. Chapter Overview
12.2. Prefilled Flush Syringes
12.2.1. Overview
12.2.2. Prefilled Flush Syringes Available in the Market
12.2.3. Advantages of Prefilled Flush Syringes
12.3. Prefilled Diluent Syringes
12.3.1. Overview
12.3.2. Lyophilized Drugs Available in Prefilled Diluent System
12.3.3. Advantages of Prefilled Diluent Syringe Systems
12.4. Contrast Agent Prefilled Syringes
12.4.1. Overview
12.4.2. Contrast Agents Available in Prefilled Syringes
12.4.3. Advantages of Using Prefilled Syringe for Contrast Agents
13. Global Prefilled Syringes Market Forecast, 2016-2026
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Global Market Size and Forecast
13.3.1. Prefilled Syringes for Vaccines
13.3.2. Prefilled Syringes for Drugs
13.3.2.1. Prefilled Syringes for Anticoagulants
13.3.2.2. Prefilled Syringes for Diabetes Drugs
13.3.2.3. Prefilled Syringes for Multiple Sclerosis Drugs
13.3.2.4. Prefilled Syringes for Anti-Arthritic Drugs
13.3.2.5. Prefilled Syringes for Anti-Anemic Drugs
13.3.2.6. Prefilled Syringes for Other Drug Classes
13.3.3. Specialty Prefilled Syringes
13.3.4. Overall Global Market Size
13.4. Prefilled Syringe Market Forecast by Regions
13.4.1. North America Prefilled Syringes Market
13.4.2. EU Prefilled Syringes Market
13.4.3. Asia Pacific Prefilled Syringes Market
13.4.4. Latin America Prefilled Syringes Market
13.4.5. Middle East and Africa Prefilled Syringes Market
13.4.6. Prefilled Syringes Market Attractiveness Analysis by Region
13.5. Prefilled Syringes Market Forecast by Type of Material
13.6. Prefilled Syringes Market Forecast by Nature of Molecule
13.6.1. Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
14. Case Study: Autoinjectors
14.1. Chapter Overview
14.2. Autoinjectors: Market Overview
14.3. Key Players
14.3.1. Bespak
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.2.1. Autoinjectors
14.3.1.2.1.1. Syrinaâ„¢
14.3.1.2.1.2. ASI Autoinjectorâ„¢
14.3.1.2.1.3. OTS Autoinjectorâ„¢
14.3.2. DALI Medical Devices
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.2.1. Autoinjectors
14.3.2.2.1.1. SAN-L
14.3.2.2.1.2. SAN-P
14.3.2.2.1.3. SAN-DV
14.3.2.2.1.4. SAN-DV Pro
14.3.3. Elcam Medical (E3D Elcam Drug Delivery Devices)
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.2.1. Autoinjectors
14.3.3.2.2. Flexi-Q Disposable Autoinjector
14.3.3.2.2.1. Flexi-Q PFS
14.3.3.2.2.2. Flexi-Q HV
14.3.3.2.2.3. Flexi -Q DV
14.3.3.2.3. Flexi-Q Reusable Autoinjectors
14.3.3.2.3.1. Flexi-Q mMU
14.3.3.2.3.2. Flexi-Q eMU
14.3.4. Nuance Designs
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.2.1. Fusionâ„¢ Autoinjector
14.3.4.2.2. Quantumâ„¢ Autoinjector
14.3.5. Owen Mumford
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.2.1. Autoinjectors
14.3.5.2.1.1. Autoject® Micro
14.3.5.2.1.2. Autoject® 2
14.3.5.2.1.3. Autoject® Mini
14.3.5.2.1.4. Autoject® Uni
14.3.5.2.1.5. Autoject® Multi
14.3.5.2.1.6. Autoject® Flex
14.3.6. Scandinavian Health Limited (SHL) Group
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.2.1. Two-Step Disposable Autoinjectors
14.3.6.2.1.1. Amber (Pushclick Technology)
14.3.6.2.1.2. Molly®
14.3.6.2.1.3. Molly® RNS
14.3.6.2.1.4. Molly® 2.25
14.3.6.2.1.5. Molly® C
14.3.6.2.1.6. NAISA® (Negasai™ Spring Technology)
14.3.6.2.2. Three-Step Disposable Autoinjectors
14.3.6.2.2.1. DAI®
14.3.6.2.2.2. DAI®-RNS
14.3.6.2.2.3. DAI®-R
14.3.6.2.2.4. SDI-MIX®+NIT™ (Needle Isolation Technology and Twist and Mix Mechanism)
14.3.6.2.2.5. VSDI-MIXâ„¢
14.3.6.2.2.6. PSDI®
14.3.6.2.3. PPI® Injector (Rotaject Pressure Release Technology)
14.3.7. Union Medico
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.2.1. 45? Autoinjector
14.3.7.2.1.1. 45?/S Autoinjector
14.3.7.2.1.2. 45?/M Autoinjector
14.3.7.2.1.3. 45?/R Autoinjector
14.3.7.2.2. 90? Autoinjector
14.3.7.2.2.1. 90?/S Autoinjector
14.3.7.2.2.2. 90?/ M Autoinjector
14.3.7.2.2.3. 90?/ XL Autoinjector
14.3.7.2.2.4. SuperGripâ„¢ Autoinjector
14.3.7.2.2.5. Exclusiveâ„¢ Autoinjector
14.3.8. Ypsomed Delivery Systems
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.2.1. Pen Injectors
14.3.8.2.2. Autoinjectors
14.3.8.2.2.1. YpsoMate® and YpsoMate® 2.25
14.3.8.2.2.2. VarioJectâ„¢
14.3.8.2.2.3. YpsoMate® Smart
15. Recent Developments and Applications of Prefilled Syringes
15.1. Chapter Overview
15.2. Prefilled Syringes for Lyophilized Drugs
15.2.1. Prefilled Diluent Syringes
15.2.2. Prefilled Dual / Multi-Chamber Syringes
15.2.2.1. Lyophilized Drugs Available in Dual / Multi-Chamber Prefilled Syringe
15.2.2.2. Prefilled Dual-Chambered Pen Injectors for Lyophilized Drugs
15.3. Multilayer Plastic Prefilled Syringes with Oxygen Barrier
15.4. Novel Lubrication Technology for Prefilled Syringes
15.5. Advancement in Terminal Sterilization of Prefilled Syringes
15.5.1. Noxilizer's Nitrogen Dioxide Sterilization Technology
16. SWOT Analysis
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
17. Conclusion
17.1. Prefilled Syringes have Emerged as the Preferred Administration Device for Parenteral Drugs
17.2. Plastic Syringes are Anticipated to Grow at Faster Rate than Glass Syringes
17.3. Emergence of Biologics, Technological Advances and Many Other Factors will Sustain the Growth
17.4. Although the Market is Consolidated, New Entrants with Innovative Technologies are expected to Drive Future Evolution
17.5. CMOs are an Integral Part of the Value Chain, Providing Aseptic Fill / Finish Services
17.6. The Prefilled Syringes Market is Poised to Grow at a Moderate Pace over the Coming Decade
17.7. Concluding Remarks
18. Interview Transcripts
18.1. Chapter Overview
18.2. Kirti Maheshwari, Chief Technical Officer, Intas Pharmaceuticals, Q3 2016
18.3. Kevin Cancelliere and Tibor Hlobik, Marketing Directors, West Pharmaceutical Services, Q2 2015
18.4. Rondald Wheet, Chief Executive Officer, Revolutions Medical, Q2 2015
18.5. Matthew Young, Founder and Chief Technology Officer, Oval Medical Technologies, Q2 2014
19. Appendix 1: Tabulated Data
20. Appendix 2: List of Companies

List of Figures
Figure 2.1 Prefilled Syringes Market Evolution: 2016, 2021, and 2026 (Number of Units, Million)
Figure 2.2 Prefilled Syringes Market Landscape, 2016-2026: Geographic Trends
Figure 2.3 Prefilled Syringes Market Attractiveness Analysis by Region
Figure 2.4 Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
Figure 3.1 Glass Prefilled Syringes: Advantages and Disadvantages
Figure 3.2 Properties of Cyclic Olefin Copolymer and Cyclo Olefin Polymer
Figure 3.3 Plastic Prefilled Syringes: Advantages and Disadvantages
Figure 3.4 Critical Design Parameters of Prefilled Syringes
Figure 3.5 Prefilled Syringes: Market Landscape by Manufacturers
Figure 3.6 Technological Evolution of Prefilled Syringes
Figure 4.1 Worldwide Evolution in Healthcare Safety Legislation
Figure 5.1 Global Regulations Related to Prefilled Syringes
Figure 5.2 Approval Pathway for Combination Products in the US
Figure 5.3 Approval Pathway for Combination Products in Canada
Figure 5.4 Approval Pathway for Combination Products in China
Figure 6.1 Global Prevalence of Diabetes: Distribution by Countries, 2015 (Million, %)
Figure 6.2 Numbers of Biologics Approved by the USFDA, 2009-2016
Figure 6.3 Top Selling Biologics: Estimated Patent Expiry
Figure 7.1 Approved Drugs: Therapeutic Area Analysis (2013-2016)
Figure 7.2 Sales of Leading Drugs Available in Prefilled Syringes, 2016 (USD Million)
Figure 7.3 HUMIRA®: Approval Timeline (US, EU and Japan)
Figure 7.4 HUMIRA®: Approval Timeline for Various Dosage Forms (US and EU)
Figure 7.5 HUMIRA®: Annual Sales, 2003-Q3 2016 (USD Million)
Figure 7.6 Enbrel®: Approval Timeline (US and EU)
Figure 7.7 Enbrel®: Approval Timeline for Various Dosage Forms (US and EU)
Figure 7.8 Enbrel®: Annual Sales in the US and Canada, 2002-2015 (USD Million)
Figure 7.9 Enbrel®: Annual Sales outside US and Canada, 2010-2015 (USD Million)
Figure 7.10 Copaxone ®: Annual Sales, 2001-Q3 2016 (USD Million)
Figure 7.11 Copaxone ®: Distribution by Vials and Prefilled Syringes, 2000-2008 (Million Units)
Figure 7.12 Lovenox®: Approval Timeline (US)
Figure 7.13 Lovenox®: Global Annual Sales, 2009- Q3 2016 (EUR Million)
Figure 7.14 Abilify Maintena®: Approval Timeline (US, Canada, Europe, Japan)
Figure 7.15 Pipeline Drugs: Therapeutic Area Analysis
Figure 7.16 Number of Approved / Pipeline Biosimilars of Anti-Rheumatics
Figure 7.17 Number of Approved / Pipeline Biosimilars of Multiple Sclerosis Drugs
Figure 7.18 Number of Approved / Pipeline Biosimilars of Antivirals
Figure 7.19 Number of Approved / Pipeline Biosimilars and Generics of Anticoagulants
Figure 7.20 Number of Approved / Pipeline Biosimilars of Diabetes Drugs
Figure 8.1 Marketed Molecules: Parameters and Scoring Criteria
Figure 8.2 Pipeline Molecules: Parameters and Scoring Criteria
Figure 9.1 BD Medical: Annual Revenues, 2011-2016 (USD Billion)
Figure 9.2 BD Medical: Revenue Distribution by Sub-Segments, 2016 (USD Billion)
Figure 9.3 Unilife Corporation: Annual Revenues, FY 2011/12-2015/16 (USD Million)
Figure 9.4 West Pharmaceutical Services: Annual Revenues, 2011-Q3 2016 (USD Million)
Figure 9.5 West Pharmaceutical Services: Revenue Distribution by Business Segments, 2015 (USD Million)
Figure 9.6 West Pharmaceutical Services: Annual Revenues of Delivery Systems Segment, 2011-2015 (USD Million)
Figure 9.7 West Pharmaceutical Services: Annual Revenues in the US and Overseas, 2011-2015 (USD Million)
Figure 9.8 West Pharmaceutical Services: Revenue Distribution by Region, 2015 (USD Million)
Figure 9.9 Gerresheimer: Annual Revenues, 2011-Q3 2016 (EUR Million)
Figure 9.10 Gerresheimer: Revenue Distribution by Business Divisions, 2015 (EUR Million)
Figure 9.11 Gerresheimer: Revenue Distribution by Region, 2011- 2015 (EUR Million)
Figure 9.12 SCHOTT: Annual Revenues, FY 2012/13-FY 2014/15 (EUR Million)
Figure 9.13 SCHOTT: Revenue Distribution by Business Divisions, FY 2014/15 (EUR Million)
Figure 9.14 SCHOTT: Revenue Distribution by Region, FY 2014/15 (EUR Million)
Figure 9.15 Nipro Corporation: Annual Revenues, 2011/12-2015/16 (YEN Billion)
Figure 9.16 Nipro Corporation: Revenue Distribution by Business Divisions, 2015/16 (YEN Billion)
Figure 9.17 Nipro Corporation: Revenue Distribution by Region, 2015/16 (YEN Billion)
Figure 9.18 Nipro Corporation: Revenue Distribution by Region, 2011/12-2015/16 (YEN Billion)
Figure 9.19 Weigao: Annual Revenues of Prefilled Syringes, 2011-H1 2016 (RMB Million)
Figure 9.20 Weigao: Revenue Distribution by Product Category, 2015 (RMB Million)
Figure 9.21 Terumo Corporation: Annual Revenues, FY 2011-H1 2016 (YEN Billion)
Figure 9.22 Terumo Corporation: Revenue Distribution by Business Divisions, FY 2015/16 (YEN Billion)
Figure 9.23 Terumo Corporation: Revenue Distribution by Region, FY 2015/16 (YEN Billion)
Figure 9.24 Glass Prefilled Syringes: Product Landscape Analysis
Figure 9.25 Polymer Prefilled Syringes: Product Landscape Analysis
Figure 10.1 Datwyler Group: Annual Revenues, 2011-H1 2016 (CHF Million)
Figure 10.2 Datwyler Group: Revenue Distribution by Business Divisions, 2015 (CHF Million)
Figure 10.3 Aptar Stelmi: Annual Revenues, 2013-2015 (USD Million)
Figure 11.1 Prefilled Syringes: Fill-Finish Process
Figure 13.1 Prefilled Syringes Price Curve, 2016-2026 (USD per unit)
Figure 13.2 Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (Million Units)
Figure 13.3 Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (USD Million)
Figure 13.4 Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (Million Units)
Figure 13.5 Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (USD Million)
Figure 13.6 Prefilled Syringes Market for Anticoagulants, 2016: Distribution by Nature of Molecule (%)
Figure 13.7 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (Million Units)
Figure 13.8 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.9 Prefilled Syringes Market for Diabetes Drugs, 2016: Distribution by Nature of Molecule (%)
Figure 13.10 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (Million Units)

Figure 13.11 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.12 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
Figure 13.13 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (Million Units)
Figure 13.14 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.15 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
Figure 13.16 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (Million units)
Figure 13.17 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.18 Prefilled Syringes Market for Anti-Anemic Drugs, 2016: Distribution by Nature of Molecule (%)
Figure 13.19 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (Million Units)
Figure 13.20 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (USD Million)
Figure 13.21 Prefilled Syringes Market for Other Drug Classes, 2016 and 2026: Distribution by Nature of Molecule (%)
Figure 13.22 Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (Millions Units)
Figure 13.23 Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Figure 13.24 Global Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
Figure 13.25 Global Prefilled Syringes, Units Growth by Category, 2016-2026 (Base Scenario, Million Units)
Figure 13.26 Global Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Figure 13.27 Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Base Scenario, USD Million)
Figure 13.28 Prefilled Syringes Market: Distribution by Regions, 2016 and 2026 (%)
Figure 13.29 North America Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
Figure 13.30 North America Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Figure 13.31 EU Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.32 EU Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.33 Asia Pacific Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.34 Asia Pacific Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.35 Latin America Prefilled Syringes Market, 2016 - 2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.36 Latin America Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.37 Middle East and Africa Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.38 Middle East and Africa Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.39 Prefilled Syringes Market Attractiveness Analysis by Region
Figure 13.40 Prefilled Syringes Market, 2016-2026: Distribution by Type of Material, Base Scenario (Million Units)
Figure 13.41 Prefilled Syringes Market, 2016-2026: Distribution by Type of Material, Base Scenario (USD Million)
Figure 13.42 Prefilled Syringes Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (Million Units)
Figure 13.43 Prefilled Syringes Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (USD Million)
Figure 13.44 Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
Figure 14.1 Bespak Injectables: Autoinjectors
Figure 14.2 Bespak Injectables: Syrinaâ„¢ Autoinjectors
Figure 14.3 DALI Medical Devices: Autoinjectors
Figure 14.4 Elcam Medical: Products
Figure 14.5 Elcam Medical: Flexi-Q Autoinjectors
Figure 14.6 Owen Mumford: Cartridge-Based Injection Pens
Figure 14.7 Owen Mumford: Autoinjectors
Figure 14.8 SHL Medical: Product Portfolio
Figure 14.9 SHL Medical: Prefilled Syringe Based Autoinjectors
Figure 14.10 SHL Medical: Cartridge Based Autoinjectors
Figure 14.11 SHL Medical: Two-Step Autoinjectors
Figure 14.12 SHL Medical: Three-Step Autoinjectors
Figure 14.13 Union Medico: 45? Autoinjector Portfolio
Figure 14.14 Union Medico: Types of 45?/R Autoinjector
Figure 14.15 Union Medico: Types of 90? Autoinjectors
Figure 14.16 Ypsomed: Cartridge Based Pen injectors
Figure 14.17 Ypsomed: Cartridge Based Dual-Chamber Pen injectors
Figure 14.18 Ypsomed: Prefilled Syringe or Cartridge Based Autoinjectors
Figure 16.1 SWOT Analysis
Figure 16.2 Common Medication Errors
Figure 16.3 Common Sources of Medication Errors
Figure 16.4 Prefilled Syringe Recalls: Distribution by Type of Issue, 2003-2016
Figure 17.1 Fill and Finish Service Providers: Distribution by Region
Figure 17.2 Prefilled Syringes Market: 2016, 2021 and 2026 (Billion Units)
Figure 17.3 Prefilled Syringes Market: 2016, 2021, and 2026 (USD Billion)


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prefilled Syringe Small Molecule Market (Therapeutic Class - Neurology Drug, Cardiovascular Drugs, Analgesics, and Adjuvants) - U.S. and EU-5 Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Prefilled Syringe Small Molecule Market (Therapeutic Class - Neurology Drug, Cardiovascular Drugs, Analgesics, and Adjuvants) - U.S. and EU-5 Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

U.S. and EU-5 Prefilled Syringe Small Molecule Market: Snapshot The prefilled syringes small molecule market was valued around US$ 12.03 Bn in 2015, accounting for significant market share of the global ...

Prefilled Syringes Market Analysis By Application (Anaphylaxis, Rheumatoid Arthritis, Diabetes, Vaccines, Hormone Replacement), By Distribution Channel (Hospitals, Mail Order Pharmacies, Ambulatory Surgery Centers), And Segment Forecasts, 2014-2025

Prefilled Syringes Market Analysis By Application (Anaphylaxis, Rheumatoid Arthritis, Diabetes, Vaccines, Hormone Replacement), By Distribution Channel (Hospitals, Mail Order Pharmacies, Ambulatory Surgery Centers), And Segment Forecasts, 2014-2025

  • $ 4950
  • Industry report
  • December 2016
  • by Grand View Research

The global prefilled syringes market size is expected to reach USD 22.5 Billion by 2025, according to a new study by Grand View Research, Inc. Key factors driving the market expansion include technological ...

Prefilled Syringes Market Analysis By Application (Anaphylaxis, Rheumatoid Arthritis, Diabetes, Vaccines, Hormone Replacement), By Distribution Channel (Hospitals, Mail Order Pharmacies, Ambulatory Surgery Centers), And Segment Forecasts, 2014 - 2025

Prefilled Syringes Market Analysis By Application (Anaphylaxis, Rheumatoid Arthritis, Diabetes, Vaccines, Hormone Replacement), By Distribution Channel (Hospitals, Mail Order Pharmacies, Ambulatory Surgery Centers), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • December 2016
  • by Grand View Research

The global prefilled syringes market size is expected to reach USD 22.5 Billion by 2025, according to a new study by Grand View Research, Inc. Key factors driving the market expansion include technological ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.